Literature DB >> 27042740

PREVENTION AND MANAGEMENT OF INSULIN-ASSOCIATED HYPOGLYCEMIA IN HOSPITALIZED PATIENTS.

Nestoras Mathioudakis, Estelle Everett, Sherita Hill Golden.   

Abstract

OBJECTIVE: To determine whether appropriate therapeutic changes in insulin doses are made to prevent and manage insulin-associated hypoglycemic events in non-critically ill hospitalized patients.
METHODS: This retrospective study was conducted in hospitalized adults on medical or surgical floors with insulin-associated hypoglycemia, excluding treatment with insulin infusions, insulin pumps, and parenteral nutrition. The first hypoglycemic event after 48 hours of admission was the index event. Over the 1-year study period, a total of 457 insulin-associated hypoglycemic events were included as index events.
RESULTS: An indication for an insulin dose adjustment was identified in 32 and 42% of patients on day -2 and day -1, respectively, before the index hypoglycemic event, of which 35 and 55%, respectively, had an insulin dose reduction ≥10%. Following the hypoglycemic event, 44% of patients had an insulin dose reduction of ≥20%. Therapeutic reduction of the total daily insulin dose by ≥20% was associated with increased odds of normoglycemia and lower odds of hyperglycemia but was not associated with lower odds of recurrent hypoglycemia on the day following the index hypoglycemic event. There was a high prevalence of hypoglycemic risk factors in this population, with kidney disease and nil per os status being the most prevalent contributing factors.
CONCLUSION: Adherence to the current practice recommendation to reduce insulin doses in patients with borderline hypoglycemia and following overt hypoglycemia was modest. Further studies are needed to understand the associated risks and to define appropriate therapeutic changes for insulin treated patients with borderline and overt hypoglycemia. ABBREVIATIONS: AKI = acute kidney injury BG = blood glucose CKD = chronic kidney disease ESRD = end-stage renal disease ICU = intensive care unit NPH = Neutral Protamine Hagedorn NPO = nil per os OR = odds ratio TDD = total daily dose.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27042740      PMCID: PMC5996396          DOI: 10.4158/EP151119.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  19 in total

1.  Implementing and evaluating a multicomponent inpatient diabetes management program: putting research into practice.

Authors:  Miguel Munoz; Peter Pronovost; Joanne Dintzis; Theresa Kemmerer; Nae-Yuh Wang; Yi-Ting Chang; Leigh Efird; Sean M Berenholtz; Sherita Hill Golden
Journal:  Jt Comm J Qual Patient Saf       Date:  2012-05

2.  American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control.

Authors:  Etie S Moghissi; Mary T Korytkowski; Monica DiNardo; Daniel Einhorn; Richard Hellman; Irl B Hirsch; Silvio E Inzucchi; Faramarz Ismail-Beigi; M Sue Kirkman; Guillermo E Umpierrez
Journal:  Endocr Pract       Date:  2009 May-Jun       Impact factor: 3.443

3.  Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities.

Authors:  Laura Boucai; William N Southern; Joel Zonszein
Journal:  Am J Med       Date:  2011-11       Impact factor: 4.965

4.  Medication incidents reported to an online incident reporting system.

Authors:  Adel Alrwisan; Jennifer Ross; David Williams
Journal:  Eur J Clin Pharmacol       Date:  2011-01-15       Impact factor: 2.953

5.  Enhancing insulin-use safety in hospitals: Practical recommendations from an ASHP Foundation expert consensus panel.

Authors:  Daniel J Cobaugh; Gregory Maynard; Lebron Cooper; Patricia C Kienle; Robert Vigersky; Diana Childers; Robert Weber; Stacy L Carson; Melanie E Mabrey; Nicki Roderman; Frederick Blum; Rebecca Burkholder; Marcus Dortch; George Grunberger; Daniel Hays; Rashida Henderson; Jeffrey Ketz; Todd Lemke; Surendra K Varma; Michael Cohen
Journal:  Am J Health Syst Pharm       Date:  2013-08-15       Impact factor: 2.637

6.  Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward.

Authors:  Alexander Turchin; Michael E Matheny; Maria Shubina; James V Scanlon; Bonnie Greenwood; Merri L Pendergrass
Journal:  Diabetes Care       Date:  2009-07       Impact factor: 19.112

7.  Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial).

Authors:  Guillermo E Umpierrez; Dawn Smiley; Ariel Zisman; Luz M Prieto; Andres Palacio; Miguel Ceron; Alvaro Puig; Roberto Mejia
Journal:  Diabetes Care       Date:  2007-05-18       Impact factor: 19.112

8.  Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial.

Authors:  Guillermo E Umpierrez; Dawn Smiley; Kathie Hermayer; Amna Khan; Darin E Olson; Christopher Newton; Sol Jacobs; Monica Rizzo; Limin Peng; David Reyes; Ingrid Pinzon; Maria Eugenia Fereira; Vicky Hunt; Ashwini Gore; Marcos T Toyoshima; Vivian A Fonseca
Journal:  Diabetes Care       Date:  2013-02-22       Impact factor: 19.112

9.  Weight-based, insulin dose-related hypoglycemia in hospitalized patients with diabetes.

Authors:  Daniel J Rubin; Denis Rybin; Gheorghe Doros; Marie E McDonnell
Journal:  Diabetes Care       Date:  2011-06-23       Impact factor: 19.112

10.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.

Authors:  Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more
  8 in total

Review 1.  How Low Can You Go? Reducing Rates of Hypoglycemia in the Non-critical Care Hospital Setting.

Authors:  Kristen Kulasa; Patricia Juang
Journal:  Curr Diab Rep       Date:  2017-09       Impact factor: 4.810

2.  Development and Validation of a Hypoglycemia Risk Model for Intensive Insulin Therapy in Patients with Type 2 Diabetes.

Authors:  Xiling Hu; Weiran Xu; Shuo Lin; Cang Zhang; Cong Ling; Miaoxia Chen
Journal:  J Diabetes Res       Date:  2020-09-19       Impact factor: 4.011

Review 3.  Inpatient Glycemic Management of Non-cardiac CVD: Focus on Stroke and PVD.

Authors:  Estelle Everett; Nestoras Mathioudakis
Journal:  Curr Diab Rep       Date:  2018-06-16       Impact factor: 4.810

4.  Retrospective Quality Improvement Study of Insulin-Induced Hypoglycemia and Implementation of Hospital-Wide Initiatives.

Authors:  Carter Shelton; Andrew P Demidowich; Mahsa Motevalli; Sam Sokolinsky; Periwinkle MacKay; Cynthia Tucker; Cora Abundo; Eileen Peters; Roliette Gooding; Margaret Hackett; Joyce Wedler; Lee Ann Alexander; Luvenia Barry; Mary Flynn; Patricia Rios; Constance Lulu Fulda; Michelle F Young; Barbara Kahl; Eileen Pummer; Nestoras N Mathioudakis; Aniket Sidhaye; Eric E Howell; Leo Rotello; Mihail Zilbermint
Journal:  J Diabetes Sci Technol       Date:  2021-04-21

5.  Internal Experts Collaborate to Reduce Critical Hypoglycemia and Insulin Errors and Improve Insulin Administration Timing.

Authors:  Kelley Szelc; Linda Nicolaus
Journal:  Clin Diabetes       Date:  2018-04

6.  Development and validation of a prediction model for insulin-associated hypoglycemia in non-critically ill hospitalized adults.

Authors:  Nestoras Nicolas Mathioudakis; Estelle Everett; Shuvodra Routh; Peter J Pronovost; Hsin-Chieh Yeh; Sherita Hill Golden; Suchi Saria
Journal:  BMJ Open Diabetes Res Care       Date:  2018-03-02

7.  Development and Validation of a Machine Learning Model to Predict Near-Term Risk of Iatrogenic Hypoglycemia in Hospitalized Patients.

Authors:  Nestoras N Mathioudakis; Mohammed S Abusamaan; Ahmed F Shakarchi; Sam Sokolinsky; Shamil Fayzullin; John McGready; Mihail Zilbermint; Suchi Saria; Sherita Hill Golden
Journal:  JAMA Netw Open       Date:  2021-01-04

Review 8.  Machine Learning Models for Inpatient Glucose Prediction.

Authors:  Andrew Zale; Nestoras Mathioudakis
Journal:  Curr Diab Rep       Date:  2022-06-27       Impact factor: 5.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.